Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-Programmed Death-1 Monoclonal Antibody, in Patients with B-Cell Malignancies

Clinical Trial Details

This clinical trial is for men and women with lymphoma for whom no standard of care options exist.

Currently available treatments for lymphoma are effective in some patients, however, others experience relapse or refractory disease following treatment. Therefore, there is a need to find more effective treatments when patients fail to respond to existing standard of care options.

Patients will be administered REGN2810 intravenously every 2 weeks at a specified dose level. Patients will receive REGN2810 for a minimum of 12 doses (24 weeks) and up to a maximum of 24 doses (48 weeks). Upon completion of treatment, there will be a 24-week follow-up period. Patients will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.

Key Eligibility: 
  • Men and women age 18 and older
  • Diagnosed with either B-cell Non-Hodgkin’s Lymphoma with active disease that is either refractory to or relapsed after most recent prior therapy for whom no standard of care options exist or documented OR
  • Hodgkin’s Lymphoma with active disease not responsive to prior therapy or relapsed after prior therapy for whom no standard of care options exist
  • Detailed eligibility reviewed when you contact the study team

Follow the Weill Cornell Lymphoma Program Online:

Study contact by location

Upper East Side - Manhattan


Amelyn Rodriguez, RN
(212) 746-1362

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:





Open to Enrollment

Age Group